Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Neuro Oncology, 24.2022, 11, S. 1935-1949
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2022
- Urheber
-
Lim, Michael
Weller, Michael
Idbaih, Ahmed
Steinbach, Joachim Peter
Finocchiaro, Gaetano
Raval, Raju R,
Ansstas, George
Bähring, Joachim
Taylor, Jennie W.
Honnorat, Jerome
Petrecca, Kevin
Vos, Filip de
Wick, Antje
Sumrall, Ashley
Sahebjam, Solmaz
Mellinghoff, Ingo K.
Kinoshita, Masashi
Roberts, Mustimbo
Slepetis, Ruta
Warad, Deepti
Leung, David
Lee, Michelle
Reardon, David A.
Omuro, Antonio
- DOI
-
10.1093/neuonc/noac116
- URN
-
urn:nbn:de:hebis:30:3-633129
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lim, Michael
- Weller, Michael
- Idbaih, Ahmed
- Steinbach, Joachim Peter
- Finocchiaro, Gaetano
- Raval, Raju R,
- Ansstas, George
- Bähring, Joachim
- Taylor, Jennie W.
- Honnorat, Jerome
- Petrecca, Kevin
- Vos, Filip de
- Wick, Antje
- Sumrall, Ashley
- Sahebjam, Solmaz
- Mellinghoff, Ingo K.
- Kinoshita, Masashi
- Roberts, Mustimbo
- Slepetis, Ruta
- Warad, Deepti
- Leung, David
- Lee, Michelle
- Reardon, David A.
- Omuro, Antonio
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2022
Ähnliche Objekte (12)
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy - the MecMeth/NOA-24 trial
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy - the MecMeth/NOA-24 trial
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy - the MecMeth/NOA-24 trial
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma